Literature DB >> 21144478

[Treatment of Alzheimer's disease and future approaches].

Françoise Forette1, Jean-Jacques Hauw.   

Abstract

The progressive neuronal loss in Alzheimer's disease leads to neurochemical abnormalities which provide the basis for symptomatic treatments. Four cholinesterase inhibitors were released in this indication. Meta-analyses have confirmed a beneficial effect on cognitive functioning and activities of daily living. The NMDA receptor antagonist, memantine, was also approved for the treatment of moderate to severe and may be associated. Progress in the patho-physiology of the disease offers some hope of new treatments acting on the cerebral lesions. The amyloid hypothesis allowed the emergence of active or passive immunotherapies, and of secretase inhibitors or modulators. Recent studies have targeted the P tau protein. The brain plasticity and the uses of stem cells offer more distant hope.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21144478     DOI: 10.2515/therapie/2010055

Source DB:  PubMed          Journal:  Therapie        ISSN: 0040-5957            Impact factor:   2.070


  1 in total

1.  Atropinic burden of prescriptions forms in patients with Alzheimer disease: a cross-sectional study in a French PharmacoVigilance Database.

Authors:  François Montastruc; Sarah Rouanet; Virginie Gardette; Vanessa Rousseau; Haleh Bagheri; Jean-Louis Montastruc
Journal:  Eur J Clin Pharmacol       Date:  2015-05-21       Impact factor: 2.953

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.